Dermira Inc. (NASDAQ:DERM) VP Christopher M. Griffith sold 1,303 shares of the firm’s stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $32.33, for a total value of $42,125.99. Following the transaction, the vice president now directly owns 45,165 shares in the company, valued at approximately $1,460,184.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Dermira Inc. (NASDAQ:DERM) traded up 1.79% during midday trading on Tuesday, reaching $32.99. The company’s stock had a trading volume of 88,884 shares. The stock has a 50 day moving average of $33.52 and a 200-day moving average of $30.24. The company’s market capitalization is $1.17 billion. Dermira Inc. has a 1-year low of $17.42 and a 1-year high of $36.16.
Dermira (NASDAQ:DERM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, equities research analysts anticipate that Dermira Inc. will post ($3.46) earnings per share for the current year.
DERM has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and set a $46.00 price target on shares of Dermira in a report on Wednesday, June 22nd. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a report on Wednesday, June 22nd. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Dermira in a report on Wednesday, October 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $41.00.
Several large investors have recently modified their holdings of the stock. Glenmede Trust Co. NA bought a new stake in shares of Dermira during the second quarter worth about $170,000. AXA bought a new stake in shares of Dermira during the first quarter worth about $1,911,000. Teachers Advisors Inc. raised its stake in shares of Dermira by 1.9% in the first quarter. Teachers Advisors Inc. now owns 123,531 shares of the biopharmaceutical company’s stock worth $2,555,000 after buying an additional 2,278 shares during the period. BlackRock Inc. raised its stake in shares of Dermira by 1.0% in the first quarter. BlackRock Inc. now owns 49,260 shares of the biopharmaceutical company’s stock worth $1,018,000 after buying an additional 499 shares during the period. Finally, American Century Companies Inc. bought a new stake in shares of Dermira during the second quarter worth about $1,352,000. Institutional investors and hedge funds own 82.57% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.